Table 1 Clinical characteristics of study subjects

N

995

141

–

Sex (male, %)

38.5%

38.3%

0.965

Age (yr)

44.8 ± 0.49

42.39 ± 1.26

0.082

Age of onset (yr)

38.82 ± 0.53

34.5 ± 1.53

0.007

Smoking status (NS/ES/SM, %)

69.6/16.6/13.7

79.4/5.0/15.6

0.002

Body mass index (kg/m2)

24.38 ± 0.11

23.65 ± 0.3

0.023

FEV1 before ASA challenge (% predicted)

83.42 ± 0.63

80.52 ± 1.76

0.124

Decline of FEV1 after ASA challenge (%)

3.83 ± 0.16

32.42 ± 1.08

1.14× 10⁻⁵³

log(PC20 methacholine (mg/mL))

0.36 ± 0.02

−0.02 ± 0.07

1.13× 10⁻⁷

Atopy (Y, %)

51.9%

48.2%

0.419

Serum total IgE (kU/L)

393.02 ± 20.22

411.2 ± 60.71

0.768

Urticaria (Y, %)

22.0%

19.9%

0.562

Water’s view (Y, %)

34.7%

59.6%

1.14× 10⁻⁸

Peripheral eosinophil count

119.88 ± 4.72

112.2 ± 13.97

0.603

Sputum eosinophil (%)

33.37 ± 1.26

32.65 ± 3.83

0.858

Sputum neutrophil (%)

5.66 ± 0.51

11.35 ± 2.31

0.018